Raul A. Sharipov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Raul A. Sharipov has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Anna Starshinova
Almazov National Medical Research Centre, St. Petersburg 197341, Russia
8 shared publications - Dmitry Anatolievich Kudlay
Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia
8 shared publications - Ravil K. Tukfatullin
Bashkir State Medical University
8 shared publications - A. R. Sabirova
Saint Petersburg State University; Federal State Budgetary Educational Institution of Higher Education “Bashkir State Medical University” of the Ministry of Health of Russia
4 shared publications - Adilya Sabirova
Department of Mathematics and Computer Science, Saint Petersburg State University, 199034 Saint Petersburg, Russia
4 shared publications Р. А. Шарипов
Федеральное государственное бюджетное образовательное учреждение высшего образования «Башкирский государственный медицинский университет» Министерства здравоохранения Российской Федерации
4 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3693
Machine-Learning-Assisted Risk Stratification for Tuberculosis Infection in High-Risk Groups Receiving Immunosuppressive Therapy
Background: Individuals receiving immunosuppressive therapy, solid-organ transplant recipients, household contacts of patients with tuberculosis, and healthcare workers are at increased risk of Mycobacterium tuberculosis infection and progression to tuberculosis disease. However, currently available immunological tests cannot reliably distinguish tuberculosis infection from active tuberculosis disease or predict individual progression to disease. We aimed to assess the prevalence of immunological evidence of tuberculosis infection across clinically and epidemiologically distinct risk groups and to explore the potential of machine-learning methods for individualised risk stratification. Methods: In this observational study, 544 adults aged 18–75 years were assessed between 2023 and 2026. Participants included patients with pulmonary tuberculosis, tuberculosis-facility healthcare workers, healthcare workers in the general medical network, household and occupational contacts of patients with tuberculosis, patients with rheumatic diseases receiving immunosuppressive therapy, patients undergoing assessment for heart transplantation, heart-transplant recipients, and healthy controls. Participants underwent clinical, epidemiological, radiological, and immunological assessment, including interferon-γ release assays (ELISPOT and QuantiFERON-TB Gold) and the tuberculosis recombinant allergen skin test. Individuals with positive immunological tests underwent additional assessment to exclude active tuberculosis. Exploratory logistic regression and decision-tree models were developed separately for each risk group using demographic and treatment-related variables. Model performance was estimated using repeated stratified 5-fold cross-validation (5 × 10 repeats) with bootstrap optimism correction; discrimination, calibration, sensitivity, specificity, positive and negative predictive values, Cohen’s kappa, and Matthews correlation coefficient were reported with 95% confidence intervals. Results: The prevalence of positive immunological tests was highest among heart-transplant recipients (15 [53.6%] of 28), followed by household contacts (12 [41.4%] of 29), patients undergoing pre-transplant assessment (5 [35.7%] of 14), and tuberculosis-facility healthcare workers (21 [22.6%] of 93). Positivity was lower among patients with rheumatic diseases receiving immunosuppressive therapy (11 [13.9%] of 79) and healthcare workers in the general medical network without documented tuberculosis exposure (7 [10.5%] of 68), and was 3 (4.4%) of 69 among healthy controls. Compared with healthy controls, positivity was significantly higher among tuberculosis-facility healthcare workers, household contacts, patients with rheumatic diseases, and pre-transplant and heart-transplant populations. Exploratory machine-learning analyses were performed separately for the two clinically most relevant immunosuppressed subgroups. In patients with rheumatic diseases (n = 71; 9 positive, 62 negative), pooled ROC AUC was 0.670 (95% CI 0.520–0.824, participant-level bootstrap); age showed 100% bootstrap sign consistency, whereas bDMARD treatment showed 84.6% and sex 55.0%. In the combined heart transplantation group (n = 41; 19 positive, 22 negative), pooled ROC AUC was 0.668 (95% CI 0.522–0.811); tacrolimus and everolimus showed the highest bootstrap sign consistency (100% and 97.6%, respectively); however, because tacrolimus and everolimus are administered predominantly to transplant recipients, these coefficients may partly reflect transplantation status rather than drug-specific effects. Because the heart transplantation group combines pre-transplant candidates and recipients, and because both subgroups had small numbers of events, these associations should be interpreted as exploratory and not as drug-specific causal effects. Conclusions: The prevalence of immunological evidence of tuberculosis infection varied substantially between risk groups and was particularly high among household contacts and heart-transplant recipients. The findings suggest that epidemiological exposure and the type of immunosuppressive therapy should be considered jointly when assessing tuberculosis infection risk. Exploratory machine-learning analyses suggested that treatment-related variables may contribute to individualised risk stratification in the combined heart transplantation group, but the models were developed in small, clinically heterogeneous subgroups and were not externally validated. They should therefore be regarded as hypothesis-generating. Prospective multicentre studies with longitudinal follow-up are required to determine whether integrated clinical, epidemiological, immunological, and treatment-related models can predict incident tuberculosis disease and improve targeted preventive strategies.
- 9 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3693
Open AccessMachine-Learning-Assisted Risk Stratification for Tuberculosis Infection in High-Risk Groups Receiving Immunosuppressive Therapy
Background: Individuals receiving immunosuppressive therapy, solid-organ transplant recipients, household contacts of patients with tuberculosis, and healthcare workers are at increased risk of Mycobacterium tuberculosis infection and progression to tuberculosis disease. However, currently available immunological tests cannot reliably distinguish tuberculosis infection from active tuberculosis disease or predict individual progression to disease. We aimed to assess the prevalence of immunological evidence of tuberculosis infection across clinically and epidemiologically distinct risk groups and to explore the potential of machine-learning methods for individualised risk stratification. Methods: In this observational study, 544 adults aged 18–75 years were assessed between 2023 and 2026. Participants included patients with pulmonary tuberculosis, tuberculosis-facility healthcare workers, healthcare workers in the general medical network, household and occupational contacts of patients with tuberculosis, patients with rheumatic diseases receiving immunosuppressive therapy, patients undergoing assessment for heart transplantation, heart-transplant recipients, and healthy controls. Participants underwent clinical, epidemiological, radiological, and immunological assessment, including interferon-γ release assays (ELISPOT and QuantiFERON-TB Gold) and the tuberculosis recombinant allergen skin test. Individuals with positive immunological tests underwent additional assessment to exclude active tuberculosis. Exploratory logistic regression and decision-tree models were developed separately for each risk group using demographic and treatment-related variables. Model performance was estimated using repeated stratified 5-fold cross-validation (5 × 10 repeats) with bootstrap optimism correction; discrimination, calibration, sensitivity, specificity, positive and negative predictive values, Cohen’s kappa, and Matthews correlation coefficient were reported with 95% confidence intervals. Results: The prevalence of positive immunological tests was highest among heart-transplant recipients (15 [53.6%] of 28), followed by household contacts (12 [41.4%] of 29), patients undergoing pre-transplant assessment (5 [35.7%] of 14), and tuberculosis-facility healthcare workers (21 [22.6%] of 93). Positivity was lower among patients with rheumatic diseases receiving immunosuppressive therapy (11 [13.9%] of 79) and healthcare workers in the general medical network without documented tuberculosis exposure (7 [10.5%] of 68), and was 3 (4.4%) of 69 among healthy controls. Compared with healthy controls, positivity was significantly higher among tuberculosis-facility healthcare workers, household contacts, patients with rheumatic diseases, and pre-transplant and heart-transplant populations. Exploratory machine-learning analyses were performed separately for the two clinically most relevant immunosuppressed subgroups. In patients with rheumatic diseases (n = 71; 9 positive, 62 negative), pooled ROC AUC was 0.670 (95% CI 0.520–0.824, participant-level bootstrap); age showed 100% bootstrap sign consistency, whereas bDMARD treatment showed 84.6% and sex 55.0%. In the combined heart transplantation group (n = 41; 19 positive, 22 negative), pooled ROC AUC was 0.668 (95% CI 0.522–0.811); tacrolimus and everolimus showed the highest bootstrap sign consistency (100% and 97.6%, respectively); however, because tacrolimus and everolimus are administered predominantly to transplant recipients, these coefficients may partly reflect transplantation status rather than drug-specific effects. Because the heart transplantation group combines pre-transplant candidates and recipients, and because both subgroups had small numbers of events, these associations should be interpreted as exploratory and not as drug-specific causal effects. Conclusions: The prevalence of immunological evidence of tuberculosis infection varied substantially between risk groups and was particularly high among household contacts and heart-transplant recipients. The findings suggest that epidemiological exposure and the type of immunosuppressive therapy should be considered jointly when assessing tuberculosis infection risk. Exploratory machine-learning analyses suggested that treatment-related variables may contribute to individualised risk stratification in the combined heart transplantation group, but the models were developed in small, clinically heterogeneous subgroups and were not externally validated. They should therefore be regarded as hypothesis-generating. Prospective multicentre studies with longitudinal follow-up are required to determine whether integrated clinical, epidemiological, immunological, and treatment-related models can predict incident tuberculosis disease and improve targeted preventive strategies.
- Open Access
- 11 October 2026
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 13 (4) , 322-338
Specifics of diagnosis and management of patients with cardiac sarcoidosis (literature review and clinical cases)
Cardiac sarcoidosis remains a diagnostic challenge and requires differential diagnosis to exclude other potential causes of pathological changes. Difficulties in diagnosis stem from the unknown aetiology of the disease, as well as the non-specific nature of its clinical manifestations. The aim of this review is to analyse data published over the last decade concerning the diagnosis of cardiac sarcoidosis. Materials and Methods . This article presents a narrative review of contemporary literature on the diagnosis of cardiac sarcoidosis. A search for publications was conducted across international and domestic electronic databases, including PubMed, Scopus, Web of Science, Google Scholar, and eLIBRARY.RU. The following keywords and their combinations were used in both English and Russian: cardiac sarcoidosis, heart transplantation for sarcoidosis, diagnosis of sarcoidosis. Results . The review predominantly includes publications from 2016–2026, alongside earlier fundamental studies and international clinical guidelines that are pivotal for understanding the issue. Selection criteria encompassed systematic reviews, meta-analyses, professional society clinical guidelines, prospective and retrospective cohort studies, and large patient registries dedicated to the diagnosis, management, and prognosis of cardiac sarcoidosis. Conclusion : This review focuses on modern diagnostic modalities and the management strategy for patients with cardiac sarcoidosis, which represents one of the most severe and prognostically unfavourable manifestations of systemic sarcoidosis. Diagnosis is frequently delayed due to non-specific symptoms and the patchy distribution of granulomatous inflammation within the myocardium. Presented case reports clearly demonstrate the capabilities of contemporary diagnostics and treatment strategies for patients with cardiac sarcoidosis.
- 11 October 2026
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 13 (4) , 322-338
Open AccessSpecifics of diagnosis and management of patients with cardiac sarcoidosis (literature review and clinical cases)
Cardiac sarcoidosis remains a diagnostic challenge and requires differential diagnosis to exclude other potential causes of pathological changes. Difficulties in diagnosis stem from the unknown aetiology of the disease, as well as the non-specific nature of its clinical manifestations. The aim of this review is to analyse data published over the last decade concerning the diagnosis of cardiac sarcoidosis. Materials and Methods . This article presents a narrative review of contemporary literature on the diagnosis of cardiac sarcoidosis. A search for publications was conducted across international and domestic electronic databases, including PubMed, Scopus, Web of Science, Google Scholar, and eLIBRARY.RU. The following keywords and their combinations were used in both English and Russian: cardiac sarcoidosis, heart transplantation for sarcoidosis, diagnosis of sarcoidosis. Results . The review predominantly includes publications from 2016–2026, alongside earlier fundamental studies and international clinical guidelines that are pivotal for understanding the issue. Selection criteria encompassed systematic reviews, meta-analyses, professional society clinical guidelines, prospective and retrospective cohort studies, and large patient registries dedicated to the diagnosis, management, and prognosis of cardiac sarcoidosis. Conclusion : This review focuses on modern diagnostic modalities and the management strategy for patients with cardiac sarcoidosis, which represents one of the most severe and prognostically unfavourable manifestations of systemic sarcoidosis. Diagnosis is frequently delayed due to non-specific symptoms and the patchy distribution of granulomatous inflammation within the myocardium. Presented case reports clearly demonstrate the capabilities of contemporary diagnostics and treatment strategies for patients with cardiac sarcoidosis.
- Open Access
- 3 October 2026
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 16 (3) , 272-280
Role of Collapse Surgery in Improving Treatment Effectiveness in Patients with Destructive Forms of Drug-Resistant Tuberculosis at the Republican Clinical Center for Phthisiology and Pulmonology (Republic of Bashkortostan, Russia)
Introduction . Multidrug resistance represents a major obstacle to tuberculosis control. Treatment of multidrug-resistant tuberculosis is lengthy, complex, and often ineffective. Surgical methods, such as thoracoplasty, can improve treatment effectiveness compared with conservative treatment. One contemporary minimally invasive approach to collapse surgery is endobronchial valve insertion, which can be performed as an independent procedure or in combination with other surgical interventions. Wider and more timely use of collapse surgery in patients with destructive tuberculosis and multiple or extensive drug resistance may shorten treatment duration and improve clinical outcomes. Materials and methods . A retrospective study was conducted at the Republican Clinical Center for Phthisiology and Pulmonology (Republic of Bashkortostan, Russia). Primary medical records, an archive of radiographic images (including CT scans), and sputum culture results obtained from the BAKLAB system based on data from the Republican Medical Information and Analytical System (RMIAS) were analyzed for 80 patients with destructive tuberculosis caused by drug-resistant pathogens. Statistical analysis was performed using the Microsoft Office software package. Differences were considered statistically significant at p < 0.05. Results and discussion . In the present study, three criteria were used to assess the effectiveness of complex treatment for destructive forms of tuberculosis. These include time to sputum culture conversion, cavity closure, and positive radiological dynamics (R-dynamics). Analysis of sputum culture conversion time in patients with destructive drug-resistant tuberculosis yielded the following results: χ² = 12.056, p = 0.061 (at the border of statistical significance). Analysis of R-dynamics yielded χ² = 7.86, p = 0.228. Statistical significance was not achieved, presumably due to the small sample size of 20 patients per group. In contrast, the difference in cavity closure rates was statistically significant: χ² = 20.04, p = 0.0027. Combined treatment was associated with a higher cavity closure rate than conservative treatment. Conclusion . The results of the study demonstrate that collapse surgery combined with chemotherapy regimens may result in faster recovery compared to treatment with a standard chemotherapy regimen alone.
- 3 October 2026
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 16 (3) , 272-280
Open AccessRole of Collapse Surgery in Improving Treatment Effectiveness in Patients with Destructive Forms of Drug-Resistant Tuberculosis at the Republican Clinical Center for Phthisiology and Pulmonology (Republic of Bashkortostan, Russia)
Introduction . Multidrug resistance represents a major obstacle to tuberculosis control. Treatment of multidrug-resistant tuberculosis is lengthy, complex, and often ineffective. Surgical methods, such as thoracoplasty, can improve treatment effectiveness compared with conservative treatment. One contemporary minimally invasive approach to collapse surgery is endobronchial valve insertion, which can be performed as an independent procedure or in combination with other surgical interventions. Wider and more timely use of collapse surgery in patients with destructive tuberculosis and multiple or extensive drug resistance may shorten treatment duration and improve clinical outcomes. Materials and methods . A retrospective study was conducted at the Republican Clinical Center for Phthisiology and Pulmonology (Republic of Bashkortostan, Russia). Primary medical records, an archive of radiographic images (including CT scans), and sputum culture results obtained from the BAKLAB system based on data from the Republican Medical Information and Analytical System (RMIAS) were analyzed for 80 patients with destructive tuberculosis caused by drug-resistant pathogens. Statistical analysis was performed using the Microsoft Office software package. Differences were considered statistically significant at p < 0.05. Results and discussion . In the present study, three criteria were used to assess the effectiveness of complex treatment for destructive forms of tuberculosis. These include time to sputum culture conversion, cavity closure, and positive radiological dynamics (R-dynamics). Analysis of sputum culture conversion time in patients with destructive drug-resistant tuberculosis yielded the following results: χ² = 12.056, p = 0.061 (at the border of statistical significance). Analysis of R-dynamics yielded χ² = 7.86, p = 0.228. Statistical significance was not achieved, presumably due to the small sample size of 20 patients per group. In contrast, the difference in cavity closure rates was statistically significant: χ² = 20.04, p = 0.0027. Combined treatment was associated with a higher cavity closure rate than conservative treatment. Conclusion . The results of the study demonstrate that collapse surgery combined with chemotherapy regimens may result in faster recovery compared to treatment with a standard chemotherapy regimen alone.
- Open Access
- 10 September 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (4) , 32-39
Detection of Latent Tuberculosis Infection in Individuals with Rheumatic Diseases Receiving Immunosuppressive Therapy
Objective : to identify latent tuberculosis infection (LTBI) in patients with rheumatic diseases receiving immunosuppressive therapy using modern methods of immunodiagnostics. Materials and methods . A combined retrospective-prospective controlled study was conducted. The study group included 79 patients with rheumatic diseases receiving immunosuppressive therapy and having no documented contact with tuberculosis (TB) patients. The control group consisted of 69 healthy individuals with no history of TB contact and no signs of exacerbated chronic diseases. All study participants underwent an interferon-gamma release assay (IGRA) and/or a skin test with a recombinant tuberculosis antigen (RTA). Results : LTBI was detected in 13.9% (11/79) of participants in the study group, which was significantly higher than in the control group (4.4% (3/69); χ²=3.944, p=0.048). During follow-up, positive RTA test results in the study group were observed in 16.1% (9/56) of cases at the second assessment and in 16.7% (6/36) of cases at the third assessment. These rates were higher than at the first (χ²=0.148, p = 0.701) and second assessments (χ²=0.006, p = 0.940), showing no statistically significant differences, although an upward trend was observed.
- 10 September 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (4) , 32-39
Open AccessDetection of Latent Tuberculosis Infection in Individuals with Rheumatic Diseases Receiving Immunosuppressive Therapy
Objective : to identify latent tuberculosis infection (LTBI) in patients with rheumatic diseases receiving immunosuppressive therapy using modern methods of immunodiagnostics. Materials and methods . A combined retrospective-prospective controlled study was conducted. The study group included 79 patients with rheumatic diseases receiving immunosuppressive therapy and having no documented contact with tuberculosis (TB) patients. The control group consisted of 69 healthy individuals with no history of TB contact and no signs of exacerbated chronic diseases. All study participants underwent an interferon-gamma release assay (IGRA) and/or a skin test with a recombinant tuberculosis antigen (RTA). Results : LTBI was detected in 13.9% (11/79) of participants in the study group, which was significantly higher than in the control group (4.4% (3/69); χ²=3.944, p=0.048). During follow-up, positive RTA test results in the study group were observed in 16.1% (9/56) of cases at the second assessment and in 16.7% (6/36) of cases at the third assessment. These rates were higher than at the first (χ²=0.148, p = 0.701) and second assessments (χ²=0.006, p = 0.940), showing no statistically significant differences, although an upward trend was observed.
- Open Access
- 29 August 2026
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 13 (3) , 206-218
Detection of latent tuberculosis infection in individuals before heart transplantation and heart transplant recipients
Background. The effective functioning of the immune system in solid organ recipients against M. tuberculosis may be compromised due to the intensive action of immunosuppressive drugs. Identifying latent tuberculosis infection (LTBI) in patients on the heart transplant waiting list, as well as in heart transplant recipients, may help improve the epidemic situation. Objective. To determent the level of latent tuberculosis infection in patients before and after heart transplantation. Materials and Methods. A comparative prospective cohort study was conducted using immunodiagnostic data from individuals prior to heart transplantation ( n =14) and recipients of a transplanted heart ( n =28). The control group consisted of healthy individuals ( n =69) with no history of contact with TB patients. All participants underwent immunodiagnosis for tuberculosis infection. Results. Positive results were recorded significantly more frequently in recipients of a transplanted heart compared to the control group (53.6 % versus 4.4 %, p =0.001). In the pre-transplant patient group, the level of positive immunodiagnostic results was also significantly higher (35.7 %) than in the control group ( p =0.001). Despite this, there were no statistically significant differences between the recipient group and the transplant candidate group ( p =0.275). Conclusion. The LTBI rate in recipients of a transplanted heart (53.6 %) was determined to be 1.5 times more frequent compared to patients awaiting transplantation (35.7 %). Notably, both comparison groups demonstrated a significantly high level of LTBI relative to healthy individuals (4.4 %), which necessitates further examination of this patient cohort and investigation into the causes of these findings.
- 29 August 2026
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 13 (3) , 206-218
Open AccessDetection of latent tuberculosis infection in individuals before heart transplantation and heart transplant recipients
Background. The effective functioning of the immune system in solid organ recipients against M. tuberculosis may be compromised due to the intensive action of immunosuppressive drugs. Identifying latent tuberculosis infection (LTBI) in patients on the heart transplant waiting list, as well as in heart transplant recipients, may help improve the epidemic situation. Objective. To determent the level of latent tuberculosis infection in patients before and after heart transplantation. Materials and Methods. A comparative prospective cohort study was conducted using immunodiagnostic data from individuals prior to heart transplantation ( n =14) and recipients of a transplanted heart ( n =28). The control group consisted of healthy individuals ( n =69) with no history of contact with TB patients. All participants underwent immunodiagnosis for tuberculosis infection. Results. Positive results were recorded significantly more frequently in recipients of a transplanted heart compared to the control group (53.6 % versus 4.4 %, p =0.001). In the pre-transplant patient group, the level of positive immunodiagnostic results was also significantly higher (35.7 %) than in the control group ( p =0.001). Despite this, there were no statistically significant differences between the recipient group and the transplant candidate group ( p =0.275). Conclusion. The LTBI rate in recipients of a transplanted heart (53.6 %) was determined to be 1.5 times more frequent compared to patients awaiting transplantation (35.7 %). Notably, both comparison groups demonstrated a significantly high level of LTBI relative to healthy individuals (4.4 %), which necessitates further examination of this patient cohort and investigation into the causes of these findings.
- Open Access
- 17 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1883
Detection of Latent Tuberculosis Infection in Patients with Rheumatological Diseases Who Receive Immunosuppressive Therapy
Background/Objectives: Latent tuberculosis infection (LTBI) is a persistent immune response to Mycobacterium tuberculosis antigens in the absence of clinically active tuberculosis. It is now established that progression from LTBI to active tuberculosis is directly associated with immune dysregulation, which frequently occurs in immune-mediated diseases requiring treatment with immunosuppressive agents. The aim of this study was to identify LTBI in patients with rheumatological diseases receiving immunosuppressive therapy using contemporary immunodiagnostic methods. Materials and Methods: A retrospective, prospective, group-control study was conducted, analyzing the results of immunodiagnostics in patients with rheumatological diseases on immunosuppressive therapy and without established contact with tuberculosis patients (n = 44; main group). The control group consisted of healthy individuals (n = 51) with no history of tuberculosis contact, clinical or radiological manifestations of the disease, or signs of chronic pathology exacerbation. Both groups were predominantly female (72.7% in the main group and 62.8% in the control group). The mean age in the patient group was 49.1 years (95% CI [44.77; 53.43]). Rheumatoid arthritis was diagnosed in 29.6% (13) of patients (95% CI [16.06; 43.03]). Articular syndrome was observed in at least 72.7% (32) of patients (95% CI [59.57; 85.89]). In 54.6% (24) of cases (95% CI [39.83; 69.26]), patients received biologic immunosuppressive therapy as basic treatment. In 15.9% (7) of cases (95% CI [5.10; 26.72]), patients received conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Of these, 71.43% (5) (95% CI [35.24; 92.44]) underwent comprehensive examination to exclude active tuberculosis prior to biologic therapy initiation. For immunodiagnostics, all subjects underwent an interferon-gamma release assay (IGRA) and/or testing with a recombinant tuberculosis antigen (ATR) sample, with dynamic assessment of test results. All patients with positive immunodiagnostic results underwent multidetector computed tomography of the chest organs. The level of LTBI in the comparison groups was defined as the percentage of positive immunological test results at a significance level of p < 0.05. Statistical data processing was performed using Microsoft Excel 2019. Results: In the main group, positive immunodiagnostic results were recorded in 20.5% (9) of cases (95% CI [8.54; 32.37]), which is significantly higher than in the control group of healthy individuals (5.8% (3), 95% CI [1.41; 16.54]). This reflects statistically significant differences in immunological test results between groups receiving and not receiving immunosuppressive therapy (χ2 = 4.545, p = 0.034). Dynamic evaluation of the ATR sample revealed positive results in 21.7% (5) of cases (95% CI [4.88; 38.60]), with four out of five patients demonstrating positive conversion. In the third assessment, positivity was observed in 33.33% (5) of cases (95% CI [9.48; 57.19]), which was higher than in the first (χ2 = 1.025, p = 0.312) and second assessments (χ2 = 0.629, p = 0.428), although these differences were not statistically significant. Notably, in two out of five patients, the ATR test result changed from negative to positive. Conclusions: In patients with rheumatological diseases receiving immunosuppressive therapy, LTBI was detected in 20.5%, which is significantly higher than in healthy individuals (5.8%, p = 0.034). Furthermore, there was an increase in the proportion of positive tests over time (up to 21.7% and 33.3% on immunotherapy), suggesting an increasing risk of progression to active tuberculosis infection.
- 17 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1883
Open AccessDetection of Latent Tuberculosis Infection in Patients with Rheumatological Diseases Who Receive Immunosuppressive Therapy
Background/Objectives: Latent tuberculosis infection (LTBI) is a persistent immune response to Mycobacterium tuberculosis antigens in the absence of clinically active tuberculosis. It is now established that progression from LTBI to active tuberculosis is directly associated with immune dysregulation, which frequently occurs in immune-mediated diseases requiring treatment with immunosuppressive agents. The aim of this study was to identify LTBI in patients with rheumatological diseases receiving immunosuppressive therapy using contemporary immunodiagnostic methods. Materials and Methods: A retrospective, prospective, group-control study was conducted, analyzing the results of immunodiagnostics in patients with rheumatological diseases on immunosuppressive therapy and without established contact with tuberculosis patients (n = 44; main group). The control group consisted of healthy individuals (n = 51) with no history of tuberculosis contact, clinical or radiological manifestations of the disease, or signs of chronic pathology exacerbation. Both groups were predominantly female (72.7% in the main group and 62.8% in the control group). The mean age in the patient group was 49.1 years (95% CI [44.77; 53.43]). Rheumatoid arthritis was diagnosed in 29.6% (13) of patients (95% CI [16.06; 43.03]). Articular syndrome was observed in at least 72.7% (32) of patients (95% CI [59.57; 85.89]). In 54.6% (24) of cases (95% CI [39.83; 69.26]), patients received biologic immunosuppressive therapy as basic treatment. In 15.9% (7) of cases (95% CI [5.10; 26.72]), patients received conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Of these, 71.43% (5) (95% CI [35.24; 92.44]) underwent comprehensive examination to exclude active tuberculosis prior to biologic therapy initiation. For immunodiagnostics, all subjects underwent an interferon-gamma release assay (IGRA) and/or testing with a recombinant tuberculosis antigen (ATR) sample, with dynamic assessment of test results. All patients with positive immunodiagnostic results underwent multidetector computed tomography of the chest organs. The level of LTBI in the comparison groups was defined as the percentage of positive immunological test results at a significance level of p < 0.05. Statistical data processing was performed using Microsoft Excel 2019. Results: In the main group, positive immunodiagnostic results were recorded in 20.5% (9) of cases (95% CI [8.54; 32.37]), which is significantly higher than in the control group of healthy individuals (5.8% (3), 95% CI [1.41; 16.54]). This reflects statistically significant differences in immunological test results between groups receiving and not receiving immunosuppressive therapy (χ2 = 4.545, p = 0.034). Dynamic evaluation of the ATR sample revealed positive results in 21.7% (5) of cases (95% CI [4.88; 38.60]), with four out of five patients demonstrating positive conversion. In the third assessment, positivity was observed in 33.33% (5) of cases (95% CI [9.48; 57.19]), which was higher than in the first (χ2 = 1.025, p = 0.312) and second assessments (χ2 = 0.629, p = 0.428), although these differences were not statistically significant. Notably, in two out of five patients, the ATR test result changed from negative to positive. Conclusions: In patients with rheumatological diseases receiving immunosuppressive therapy, LTBI was detected in 20.5%, which is significantly higher than in healthy individuals (5.8%, p = 0.034). Furthermore, there was an increase in the proportion of positive tests over time (up to 21.7% and 33.3% on immunotherapy), suggesting an increasing risk of progression to active tuberculosis infection.
- Open Access
- 22 March 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (1) , 100-113
Advances in Detecting Latent Tuberculosis Infection in High-Risk Groups: from Immunodiagnostics to Machine Learning (Systematic Review)
The detection of latent tuberculosis infection (LTBI) is essential for improving the epidemiological situation in the region. As tuberculosis prevalence declines, identifying LTBI in risk groups becomes increasingly significant. At present, no method exists that can reliably confirm or exclude the presence of latent tuberculosis infection. In this study, we analyzed 71 publications on methods for LTBI detection, including modern immunological tests based on Mycobacterium tuberculosis antigens ESAT-6 and CFP-10, as well as interferon-γ release assays (IGRAs). Developing diagnostic strategies for LTBI is particularly relevant for individuals with diabetes mellitus, congenital or acquired immunodeficiency, those receiving immunosuppressive therapy, patients undergoing hemodialysis, as well as for children and the elderly. The search for novel LTBI biomarkers using artificial intelligence, aimed at improving detection and predicting the progression to active tuberculosis seems to be promising advancement in phthisiology.
- 22 March 2026
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 104 (1) , 100-113
Open AccessAdvances in Detecting Latent Tuberculosis Infection in High-Risk Groups: from Immunodiagnostics to Machine Learning (Systematic Review)
The detection of latent tuberculosis infection (LTBI) is essential for improving the epidemiological situation in the region. As tuberculosis prevalence declines, identifying LTBI in risk groups becomes increasingly significant. At present, no method exists that can reliably confirm or exclude the presence of latent tuberculosis infection. In this study, we analyzed 71 publications on methods for LTBI detection, including modern immunological tests based on Mycobacterium tuberculosis antigens ESAT-6 and CFP-10, as well as interferon-γ release assays (IGRAs). Developing diagnostic strategies for LTBI is particularly relevant for individuals with diabetes mellitus, congenital or acquired immunodeficiency, those receiving immunosuppressive therapy, patients undergoing hemodialysis, as well as for children and the elderly. The search for novel LTBI biomarkers using artificial intelligence, aimed at improving detection and predicting the progression to active tuberculosis seems to be promising advancement in phthisiology.
- Open Access
Detection for New Biomarkers of Tuberculosis Infection Activity Using Machine Learning Methods
Background/Objectives: Latent tuberculosis infection (LTBI) represents a critical reservoir for subsequent development of active tuberculosis (ATB) and poses significant challenges for early diagnosis and disease prevention. Traditional immunological assays, such as interferon-gamma release assays (IGRAs), are limited in their ability to reliably distinguish LTBI from ATB. Recent advances in high-throughput omics technologies and machine learning (ML) approaches offer new opportunities for precise, biomarker-based differential diagnostics. Methods: Transcriptomic and proteomic profiling of host immune responses has revealed reproducible gene and protein signatures associated with LTBI and ATB. The integration of ML techniques—including feature selection, dimensionality reduction, multimodal learning, and explainable AI—facilitates the construction of robust diagnostic models. Single-modality signatures, derived from RNA-seq, microarrays, or proteomic assays, are complemented by multimodal approaches that incorporate soluble mediators, immunological readouts, and imaging-derived features. Deep learning frameworks, such as convolutional neural networks and transformer-based architectures, enhance the extraction of complex molecular and structural patterns from high-dimensional datasets. Results: ML-driven analyses of transcriptomic and proteomic data consistently outperform conventional immunological tests in terms of sensitivity, specificity, and clinical applicability. Multimodal integration further improves diagnostic accuracy and robustness. These advances support the translational development of concise, quantitative reverse transcription PCR (qRT-PCR)-based biomarker panels suitable for routine clinical application, enabling early and reliable differentiation between LTBI and ATB. Overall, the combination of high-throughput omics and AI-based analytical frameworks provides a promising pathway for enhancing global tuberculosis diagnostics. Conclusions: This review provides a structured and critical synthesis of transcriptomic and proteomic biomarker research for LTBI and ATB discrimination, with a particular emphasis on machine learning–based analytical frameworks. Unlike previous narrative reviews, we systematically compare data-generating platforms, modelling strategies, validation approaches, and sources of heterogeneity across studies. We further identify key translational barriers, including cohort homogeneity, platform dependency, and limited external validation, and propose directions for future research aimed at improving clinical applicability.
Open AccessDetection for New Biomarkers of Tuberculosis Infection Activity Using Machine Learning Methods
Background/Objectives: Latent tuberculosis infection (LTBI) represents a critical reservoir for subsequent development of active tuberculosis (ATB) and poses significant challenges for early diagnosis and disease prevention. Traditional immunological assays, such as interferon-gamma release assays (IGRAs), are limited in their ability to reliably distinguish LTBI from ATB. Recent advances in high-throughput omics technologies and machine learning (ML) approaches offer new opportunities for precise, biomarker-based differential diagnostics. Methods: Transcriptomic and proteomic profiling of host immune responses has revealed reproducible gene and protein signatures associated with LTBI and ATB. The integration of ML techniques—including feature selection, dimensionality reduction, multimodal learning, and explainable AI—facilitates the construction of robust diagnostic models. Single-modality signatures, derived from RNA-seq, microarrays, or proteomic assays, are complemented by multimodal approaches that incorporate soluble mediators, immunological readouts, and imaging-derived features. Deep learning frameworks, such as convolutional neural networks and transformer-based architectures, enhance the extraction of complex molecular and structural patterns from high-dimensional datasets. Results: ML-driven analyses of transcriptomic and proteomic data consistently outperform conventional immunological tests in terms of sensitivity, specificity, and clinical applicability. Multimodal integration further improves diagnostic accuracy and robustness. These advances support the translational development of concise, quantitative reverse transcription PCR (qRT-PCR)-based biomarker panels suitable for routine clinical application, enabling early and reliable differentiation between LTBI and ATB. Overall, the combination of high-throughput omics and AI-based analytical frameworks provides a promising pathway for enhancing global tuberculosis diagnostics. Conclusions: This review provides a structured and critical synthesis of transcriptomic and proteomic biomarker research for LTBI and ATB discrimination, with a particular emphasis on machine learning–based analytical frameworks. Unlike previous narrative reviews, we systematically compare data-generating platforms, modelling strategies, validation approaches, and sources of heterogeneity across studies. We further identify key translational barriers, including cohort homogeneity, platform dependency, and limited external validation, and propose directions for future research aimed at improving clinical applicability.
- Open Access
Alterations in the Immune Response in Individuals with Latent Tuberculosis Infection
Latent tuberculosis infection (LTBI) represents a biologically active yet clinically asymptomatic stage of Mycobacterium tuberculosis (Mtb) persistence. This condition is characterized by subtle immunometabolic alterations reflecting the host–pathogen equilibrium. Understanding the mechanisms and biomarkers associated with the preclinical phase of LTBI is crucial for preventing progression to active tuberculosis (ATB). Recent advances have identified multiple immunological, transcriptomic, metabolic, and imaging-based approaches that enable stratification of individuals at increased risk of LTBI reactivation. Quantitative assays such as IGRA, multiplex and T-cell activation marker (TAM) tests, as well as interferon-related transcriptional signatures, demonstrate predictive potential when combined with functional assays (MGIA) and metabolic imaging (PET/CT). Experimental primate models faithfully reproduce the spectrum from latency to reactivation, allowing for validation of biomarkers and vaccine or immunomodulatory strategies. The review also highlights the particular challenges of multidrug-resistant LTBI (MDR-LTBI), where standard chemoprophylaxis is less effective and immune control plays a decisive role. The preclinical phase of LTBI constitutes a key point in the TB control cascade. Integrating immunological, transcriptomic, and radiological data into risk-based screening algorithms could substantially improve early detection and targeted prevention. Translating research-derived signatures into clinically applicable, standardized, and cost-effective diagnostic tools requires coordinated international efforts, technological transfer, and policy-level support to reduce TB reactivation and transmission, including MDR-TB.
Open AccessAlterations in the Immune Response in Individuals with Latent Tuberculosis Infection
Latent tuberculosis infection (LTBI) represents a biologically active yet clinically asymptomatic stage of Mycobacterium tuberculosis (Mtb) persistence. This condition is characterized by subtle immunometabolic alterations reflecting the host–pathogen equilibrium. Understanding the mechanisms and biomarkers associated with the preclinical phase of LTBI is crucial for preventing progression to active tuberculosis (ATB). Recent advances have identified multiple immunological, transcriptomic, metabolic, and imaging-based approaches that enable stratification of individuals at increased risk of LTBI reactivation. Quantitative assays such as IGRA, multiplex and T-cell activation marker (TAM) tests, as well as interferon-related transcriptional signatures, demonstrate predictive potential when combined with functional assays (MGIA) and metabolic imaging (PET/CT). Experimental primate models faithfully reproduce the spectrum from latency to reactivation, allowing for validation of biomarkers and vaccine or immunomodulatory strategies. The review also highlights the particular challenges of multidrug-resistant LTBI (MDR-LTBI), where standard chemoprophylaxis is less effective and immune control plays a decisive role. The preclinical phase of LTBI constitutes a key point in the TB control cascade. Integrating immunological, transcriptomic, and radiological data into risk-based screening algorithms could substantially improve early detection and targeted prevention. Translating research-derived signatures into clinically applicable, standardized, and cost-effective diagnostic tools requires coordinated international efforts, technological transfer, and policy-level support to reduce TB reactivation and transmission, including MDR-TB.
- Open Access
- 1 July 2025
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 15 (2) , 64-74
Differential Diagnosis of Peripheral Lung Lesions: Capabilities and Limitations of Current Methods
This article analyzes 63 scientific works dedicated to the diagnosis of peripheral lung lesions (PLL). The differential diagnosis of PLL poses challenges due to the diversity of underlying pathologies, which may include tuberculoma, cancer, and benign tumors. The absence of a unified diagnostic algorithm often necessitates surgical intervention. Non-invasive methods, including radiography, computed tomography (CT), positron emission tomography (PET), and sputum analysis, exhibit limited diagnostic yield, particularly for small lesions. The combination of fiberoptic bronchoscopy with endoscopic ultrasound (EUS) and transthoracic biopsy enhances diagnostic accuracy; however, they carry risks such as pneumothorax. Video-assisted thoracoscopic surgery (VATS) is an effective modality when biopsies are inconclusive, especially for lesions of less than 3 cm. It ensures high diagnostic accuracy and reduces hospitalization duration. Videoassisted thoracoscopic biopsy offers diagnostic accuracy comparable to that of open biopsy, while exhibiting reduced invasiveness. Conventional thoracotomy remains indicated for large or hard-to-reach lesions. It is recommended that a comprehensive approach combining CT, characterized by high informative value, and PET scan, characterized by high sensitivity and specificity for nodules >10 mm, with invasive methods be used. VATS proves effective for lesions below 3 cm, while thoracotomy is applied to large lesions. An individualized approach remains essential for optimal diagnosis. Despite the advancements, the challenge of differential diagnosis persists.
- 1 July 2025
- Published by Bashkir State Medical University in Creative surgery and oncology
- Vol. 15 (2) , 64-74
Open AccessDifferential Diagnosis of Peripheral Lung Lesions: Capabilities and Limitations of Current Methods
This article analyzes 63 scientific works dedicated to the diagnosis of peripheral lung lesions (PLL). The differential diagnosis of PLL poses challenges due to the diversity of underlying pathologies, which may include tuberculoma, cancer, and benign tumors. The absence of a unified diagnostic algorithm often necessitates surgical intervention. Non-invasive methods, including radiography, computed tomography (CT), positron emission tomography (PET), and sputum analysis, exhibit limited diagnostic yield, particularly for small lesions. The combination of fiberoptic bronchoscopy with endoscopic ultrasound (EUS) and transthoracic biopsy enhances diagnostic accuracy; however, they carry risks such as pneumothorax. Video-assisted thoracoscopic surgery (VATS) is an effective modality when biopsies are inconclusive, especially for lesions of less than 3 cm. It ensures high diagnostic accuracy and reduces hospitalization duration. Videoassisted thoracoscopic biopsy offers diagnostic accuracy comparable to that of open biopsy, while exhibiting reduced invasiveness. Conventional thoracotomy remains indicated for large or hard-to-reach lesions. It is recommended that a comprehensive approach combining CT, characterized by high informative value, and PET scan, characterized by high sensitivity and specificity for nodules >10 mm, with invasive methods be used. VATS proves effective for lesions below 3 cm, while thoracotomy is applied to large lesions. An individualized approach remains essential for optimal diagnosis. Despite the advancements, the challenge of differential diagnosis persists.